000963
vs
Shanghai Composite
Over the past 12 months, has underperformed Shanghai Composite, delivering a return of -9% compared to the Shanghai Composite's 10% growth.
Stocks Performance
000963 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
US |
Mckesson Corp
NYSE:MCK
|
||
US |
Cencora Inc
NYSE:COR
|
||
US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
|
US |
Cardinal Health Inc
NYSE:CAH
|
||
US |
Henry Schein Inc
NASDAQ:HSIC
|
||
KR |
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
||
CN |
Sinopharm Group Co Ltd
HKEX:1099
|
||
CN |
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
||
IT |
Amplifon SpA
MIL:AMP
|
||
DE |
M
|
McKesson Europe AG
XHAM:CLS1
|
Performance Gap
000963 vs Shanghai Composite
US |
Mckesson Corp
NYSE:MCK
|
||
US |
Cencora Inc
NYSE:COR
|
||
US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
|
US |
Cardinal Health Inc
NYSE:CAH
|
||
US |
Henry Schein Inc
NASDAQ:HSIC
|
||
KR |
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
||
CN |
Sinopharm Group Co Ltd
HKEX:1099
|
||
CN |
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
||
IT |
Amplifon SpA
MIL:AMP
|
||
DE |
M
|
McKesson Europe AG
XHAM:CLS1
|
Performance By Year
000963 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
US |
Mckesson Corp
NYSE:MCK
|
||
US |
Cencora Inc
NYSE:COR
|
||
US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
|
US |
Cardinal Health Inc
NYSE:CAH
|
||
US |
Henry Schein Inc
NASDAQ:HSIC
|
||
KR |
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
||
CN |
Sinopharm Group Co Ltd
HKEX:1099
|
||
CN |
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
||
IT |
Amplifon SpA
MIL:AMP
|
||
DE |
M
|
McKesson Europe AG
XHAM:CLS1
|
Competitors Performance
Huadong Medicine Co Ltd vs Peers
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
US |
G
|
GE Vernova LLC
NYSE:GEV
|
|
NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
|
US |
Schlumberger NV
NYSE:SLB
|
||
US |
B
|
Baker Hughes Co
NASDAQ:BKR
|
|
ID |
Amman Mineral Internasional Tbk PT
IDX:AMMN
|
||
US |
R
|
Reddit Inc
NYSE:RDDT
|
|
CH |
G
|
Galderma Group AG
SIX:GALD
|
|
US |
Halliburton Co
NYSE:HAL
|
||
LU |
Tenaris SA
MIL:TEN
|
||
IN |
Jio Financial Services Ltd
NSE:JIOFIN
|
Huadong Medicine Co Ltd
Glance View
Huadong Medicine Co., Ltd., a key player in China's pharmaceutical landscape, was established with a vision to integrate research, development, manufacturing, and distribution of pharmaceutical products. The company operates a diverse portfolio comprising prescription medicines, over-the-counter products, and active pharmaceutical ingredients. Central to its strategy is a robust focus on innovation and quality, enabling it to effectively cater to various therapeutic areas, including oncology, endocrinology, and nephrology. Huadong Medicine benefits from its substantial investment in research and development, with state-of-the-art facilities that drive advancements and partnerships with global biotech firms, thereby underscoring its commitment to bringing cutting-edge medical solutions to the market. At the heart of Huadong Medicine’s business model is a well-coordinated infrastructure that seamlessly blends manufacturing excellence with a sophisticated distribution network. This dynamic framework ensures the efficient delivery of products across China and into international markets, supporting a significant revenue stream. Additionally, the company's active pharmaceutical ingredients (API) division forms a crucial component of its operations, supplying high-quality raw materials to both domestic and international pharmaceutical companies. By maintaining a strategic balance between product innovation and operational efficiency, Huadong Medicine not only sustains its competitive advantage but also continually scales its presence in the global pharmaceutical industry, carving out a prominent niche in an increasingly competitive arena.